• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Claritin-D 24 Hour Extended Release Tablets (10 mg loratadine, 240 mg pseudoephedrine sulfate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Claritin-D 24 Hour Extended Release Tablets (10 mg loratadine, 240 mg pseudoephedrine sulfate)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Claritin-D 24 Hour Extended Release Tablets (10 mg loratadine, 240 mg pseudoephedrine sulfate), a new once-daily formulation of the widely prescribed nonsedating antihistamine/decongestant combination Claritin-D (5 mg loratadine, 120 mg pseudoephedrine sulfate), has been approved for marketing.

    Available by prescription, Claritin-D 24 Hour provides relief of nasal symptoms and congestion for a full 24-hour period with one daily dose.

    Claritin-D 24 Hour is indicated for the relief of seasonal allergic rhinitis (hay fever) wit nasal congestion, a common symptom among many allergy sufferers.

    Claritin-D 24 Hour, which will be available nationwide by prescription in early September, can be administered to adults and children 12 years of age and older. The recommended dose is one tablet, once daily.

    Clinical Results

    In clinical trials, improvement in nasal and non-nasal symptoms of seasonal allergic rhinitis including nasal congestion in subjects receiving Claritin-D 24 Hour tablets was significantly greater than in placebo recipients, and was generally greater than with loratadine or pseudoephedrine sulfate alone

    Side Effects

    Insomnia is a common side effect of many drugs containing pseudoephedrine. However, Claritin-D 24 Hour has a low incidence of insomnia, occurring in only 5% of subjects. Other commonly reported side effects using the recommended dose of Claritin-D 24 Hour occurred as a rate similar to placebo and included sedation (6%) and nervousness (3%). Dry mouth occurred in 8% of subjects.

    Additional Information

    It is estimated that 16 million of the 42 million Americans who suffer from seasonal allergic rhinitis also experience nasal congestion.

    Approval Date: 1996-08-01
    Company Name: Schering-Plough
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing